Table 3 Summary of data obtained from different studies on kidney dosimetry for 177 Lu octreotate
The present study, Gothenburg | Valkema et al., Rotterdam [ [18]] | Garkavij, et al., Lund [ [20]] | Sandström et al., Uppsala [ [19]] | Wehrmann et al., Bad Berka [ [17]] | Cremonesi et al., Milan [ [15]] | |
|---|---|---|---|---|---|---|
Kidney protection | Lysine, arginine | Lysine, arginine | Vamin | Vamin | Lysine, arginine | ND |
Number of patients | 33 | 37 | 16 | 24 | 61 | 10 |
A administered/treatment cycle (GBq) mean (range) | (3.4 to 8.2) | (1.8 to 7.4) | 7.4 | 7.4 | 5.4 (2.5 to 7.4) | (3.7 to 7.4) |
Treatment cycles per patient | 1 to 5 | 3 to 7 | 2 to 4 | Only first treatment cycle | 1 to 4 | ND |
D/A administered (Gy/GBq) mean (SD) | 0.80 (0.30), 0.60 (0.17)* | 0.97 (0.24), 1.15 (0.29)*, 0.81 (0.21)**, 0.90 (0.21)*** | 0.98 (0.73), 0.71 (0.25)*, 0.65 (0.25)** | 0.9 (0.3) | 0.62 (median) | |
D/A administered (Gy/GBq) range | 0.33 to 2.4 Gy/GBq, 0.29 to 1.2 Gy/GBq* | 7.3 to 27 Gy | 2.4 to 13 Gy (right)** | 0.5 to 1.7 Gy/GBq | 0.45 to 18 Gy/GBq (median range) | |
D/A administered for treatment cycle 1 (Gy/GBq) mean (range) (SD) | 0.84 (0.38 to 1.7) (0.29) | 0.98 (0.73), 0.71 (0.25)*, 0.65 (0.25)** | ||||
Imaging time points | 1 h, days 1, 2, and 7 | ND, but several days | 0.5 h, days 1, 4, and 7 (treatment cycle 1 to 2) days 1,and 4 (treatment cycle 3 to 4) SPECT at day1 and/or day 4 | 1 h, days 1, 4, and 7 (treatment cycle 1) SPECT at all time points | 0, 3, 20, 44, and 68 h | up to 48 h |
Scintigraphic method | Planar imaging | Planar imaging | Planar imaging, SPECT | Planar imaging, SPECT | Planar imaging | Planar imaging |
Quantification method | CV, *PA, CT for kidney mass | CV | CV attenuation map CT for kidney mass, *different background, **SPECT to scale the time-activity curve, ***SPECT for voxel dosimetry | *SPECT organ VOI, **SPECT small VOI (4 cm3) | CV | CV |
Dosimetry | MIRD | MIRDOSE3 | MIRD | OLINDA | MIRD 16, MEDISO, OLINDA with S values for absorbed dose calculation | OLINDA/EXM |